Lutetium-177 PSMA therapy represents one of the most significant advances in prostate cancer treatment in recent years — a form of precision medicine that delivers targeted radiation directly to cancer cells, wherever they are in the body, while leaving most healthy tissue untouched. Approved by the U.S. Food and Drug Administration (FDA) in March 2022 and by the European Medicines Agency (EMA) in December 2022, this treatment has given new options to patients with advanced prostate cancer who have exhausted standard therapies. Here is what it is, how it works, and how Medical E-Aid can help patients access it.

What is Lutetium-177 PSMA therapy?

Lutetium-177 PSMA therapy — also known by the brand name Pluvicto (177Lu-PSMA-617 or lutetium vipivotide tetraxetan) — is a radioligand therapy (RLT): a drug that combines a radioactive element with a molecule that seeks out and binds to a specific target on cancer cells. In this case, the target is prostate-specific membrane antigen (PSMA), a protein that is overexpressed on the surface of prostate cancer cells — often far more abundantly than on normal tissue — making it an almost ideal molecular target.

The therapy belongs to a broader field called theranostics: the same PSMA-targeting ligand can be paired with a diagnostic radiotracer (such as gallium-68) to produce a PET-CT scan that visualises exactly where PSMA-expressing cancer cells are located in the body. If the scan confirms high PSMA expression, the patient may be a candidate to receive the same ligand paired with lutetium-177, which delivers localised radiation therapy to those same sites.

How does it work?

After an intravenous infusion, the lutetium-177–labelled compound circulates in the bloodstream and homes in on PSMA-expressing cells. Once it binds, the radioactive lutetium-177 emits beta radiation — a short-range, high-energy particle — that damages the DNA of the cancer cell from within, causing cell death. Because the range of beta radiation is only a few millimetres in tissue, the damage is largely confined to the tumour cells and their immediate microenvironment, sparing surrounding healthy structures.

Treatment is given as an intravenous infusion approximately every six weeks, with a standard course of up to six cycles. It is administered on an outpatient or short-stay basis at specialist nuclear medicine or oncology centres equipped for radionuclide therapy.

Who is it for?

Current approval covers adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) — that is, prostate cancer that has spread to other parts of the body and is no longer responding to hormone-suppression therapy — who have previously received androgen receptor pathway inhibitors and taxane-based chemotherapy. A PSMA PET-CT scan is performed first to confirm that the patient’s cancer expresses sufficient PSMA for the treatment to be effective.

Ongoing research is also evaluating 177Lu-PSMA in earlier lines of treatment, including patients who are not yet eligible for, or who cannot tolerate, chemotherapy, and in castration-sensitive settings — broadening the potential population who may benefit.

What do the clinical outcomes show?

The pivotal evidence comes from the VISION phase III trial, published in the New England Journal of Medicine (2021). In patients with mCRPC who had progressed on prior standard therapies, adding 177Lu-PSMA-617 to standard care significantly improved outcomes. Published data from the trial report that the treatment reduced the risk of radiographic progression or death by approximately 60% and reduced the risk of death from any cause by approximately 38% compared with standard-of-care therapy alone. Median overall survival improved from approximately 11.3 months to 15.3 months — a four-month gain in a heavily pre-treated population where options are limited.

PSA response rates (a marker of treatment activity) were also meaningfully higher in the treatment group. These figures reflect the published trial data and are presented here for informational purposes; individual outcomes will vary depending on disease extent, prior treatment history, and patient-specific factors.

Benefits at a glance

• Highly targeted — radiation is delivered directly to PSMA-expressing cancer cells throughout the body, including bone and lymph node metastases
• Theranostic approach — the same diagnostic scan that identifies eligible patients also guides and monitors treatment, enabling a truly personalised strategy
• Systemic reach — treats metastatic disease at multiple sites simultaneously, unlike surgery or external-beam radiotherapy which address single lesions
• Generally well-tolerated — the most commonly reported side effects in clinical trials include fatigue, dry mouth (xerostomia), nausea, and changes in blood counts; serious adverse events occur in a minority of patients
• Outpatient delivery — most patients receive each infusion on a day-clinic basis and return home the same day

What to expect during treatment

Before starting, patients undergo a PSMA PET-CT scan (often with gallium-68 or fluorine-18 labelled PSMA tracer) to confirm eligibility. A multidisciplinary team — typically including a nuclear medicine physician, radiation oncologist, and urologist — reviews the scan and the patient’s history to determine suitability.

Each infusion takes approximately 30–60 minutes. Because the patient briefly becomes mildly radioactive after each session, standard radiation-safety precautions are followed for a short period — typically 24–48 hours — including limiting close contact with young children and pregnant women. Patients are monitored with blood tests between cycles to check kidney function and blood counts. Most patients tolerate the treatment course well enough to maintain normal day-to-day activities between infusions.

Accessing Lutetium-177 PSMA therapy with Medical E-Aid

Lutetium-177 PSMA therapy requires specialist nuclear medicine infrastructure and a multidisciplinary oncology team experienced in theranostics — capabilities found at leading cancer centres globally. Medical E-Aid connects patients with accredited centres offering this therapy and coordinates the entire process: case review, PSMA PET-CT eligibility assessment, treatment planning, travel and accommodation logistics, interpretation support, and follow-up coordination. Our AI pre-screening reviews your documentation and helps match your case to the right specialist team, so you spend less time navigating and more time focused on treatment.

This article is for general information only and does not constitute medical advice. Treatment eligibility depends on each patient’s diagnosis, disease stage, PSMA expression level, and prior treatment history, and must be determined by qualified specialists. Outcome figures cited are drawn from published clinical trial data and may not reflect individual results.

Sources: Sartor O et al., “Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer,” New England Journal of Medicine 385:1091–1103 (2021) — PMC8446332; U.S. Food & Drug Administration, Pluvicto Approval (March 2022); Hofman MS et al., “Prostate-specific membrane antigen theranostics: therapy with lutetium-177,” Current Opinion in Urology 28(2):197–204 (2018) — PubMed 29278583; National Cancer Institute (cancer.gov) — Lutetium Lu 177 Vipivotide Tetraxetan; Albernaz V et al., “A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer,” PMC9584169.